Last reviewed · How we verify

NCT01109420

Clinical and Genetic Studies in Familial Non-medullary Thyroid Cancer

Recruiting now Last updated 9 March 2026
What this trial tests

trial in Non-Medullary Thyroid Cancer in 500 participants. Currently enrolling.

Timeline
12 August 2010

Quick facts

Lead sponsorNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment500
Start date12 August 2010
Sites1 location across United States

Conditions studied

Sponsor

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Who can join

Adults 7 to 90, any sex, with Non-Medullary Thyroid Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Background: \- Researchers are studying types of thyroid cancer that seem to cluster in families. Non-medullary thyroid cancer accounts for the vast majority of all types of thyroid cancer, but little is known about possible genes that may cause the cancer. More research is needed to develop the best ways to screen for familial non-medullary thyroid cancer (FNMTC) so that it can be diagnosed and treated at an early stage. Objectives: * To evaluate the natural history of FNMTC. * To determine the best screening strategy for FNMTC. * To identify genes that may indicate susceptibility to FNMTC. Eligibility: \- Individuals at least 7 years of age who have two first-degree relatives (e.g., parents, children, siblings) who have or have had non-medullary thyroid cancer or a documented diagnosis of non-medullary thyroid cancer and one living relative with documented non-medullary thyroid cancer. Design: * Participants will be evaluated by family history pedigree, physical examination, imaging (including possible neck ultrasound and radioactive iodine scans), and laboratory testing. * Participants who agree to have blood or other biological samples collected will be asked to enroll in an additional study to provide the appropriate samples and tissues. * After the initial study evaluation, participants who are not found to have a malignant thyroid tumor will be re-screened every year with non-invasive imaging studies. Participants who are found to have a malignant thyroid tumor will be informed of possible treatment options.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. SAT-329 Impact of Familial Non-medullary Thyroid Cancer on Quality of Life: A Comparative Study of Affected and Unaffected Family Members
    · 2025

Verify or expand the search:

Other National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01109420.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing